INT109327

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 42
Total Number 45
Disease Relevance 43.20
Pain Relevance 2.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KIT) extracellular space (KIT) plasma membrane (KIT)
nucleus (KIT) cytoplasm (KIT)
Anatomy Link Frequency
platelet 5
thyroid 2
Hair 2
stroma 1
germ cells 1
KIT (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 8 100.00 Very High Very High Very High
cytokine 54 98.64 Very High Very High Very High
Hippocampus 3 98.32 Very High Very High Very High
cva 25 97.80 Very High Very High Very High
pruritus 17 90.84 High High
Pain 54 88.04 High High
Dysuria 1 83.56 Quite High
nud 8 82.00 Quite High
abdominal pain 13 81.72 Quite High
Potency 4 80.48 Quite High
Disease Link Frequency Relevance Heat
Ovarian Cancer 413 99.96 Very High Very High Very High
Fibromyalgia 12 99.68 Very High Very High Very High
Disease 584 99.62 Very High Very High Very High
Pigment Disorder 16 99.58 Very High Very High Very High
Shock 5 99.44 Very High Very High Very High
Cancer 1413 99.32 Very High Very High Very High
Gastrointestinal Stromal Tumor 593 99.32 Very High Very High Very High
Breast Cancer 155 99.24 Very High Very High Very High
Apoptosis 186 99.16 Very High Very High Very High
Chronic Myeloid Leukemia 10 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib (Gleevec, Novartis, Basel, Switzerland) is a recently developed selective inhibitor of several tyrosine kinases including KIT.
Negative_regulation (inhibitor) of KIT
1) Confidence 0.57 Published 2008 Journal World J Surg Oncol Section Body Doc Link PMC2567321 Disease Relevance 0.96 Pain Relevance 0
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R).
Negative_regulation (inhibitor) of KIT in platelet
2) Confidence 0.53 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 0.70 Pain Relevance 0
It specifically targets the c-kit (CD117) proto-oncogene gain of function mutation characterising GISTs, blocking the c-kit kinase, leading to growth cessation and significant durable clinical remissions.
Negative_regulation (blocking) of kit
3) Confidence 0.43 Published 2004 Journal BMC Cancer Section Body Doc Link PMC524360 Disease Relevance 0.81 Pain Relevance 0.04
An additional agent is associated with the expression and inhibition of CD117 (c-kit), and has been effectively used in various neoplasms such as hematological malignancies and gastrointestinal stromal tumors (GIST).
Negative_regulation (inhibition) of CD117 associated with cancer, hematologic neoplasms and gastrointestinal stromal tumor
4) Confidence 0.43 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 1.61 Pain Relevance 0.05
Mast cells are dependent on the autocrine circle of CD117 [1], and the loss of CD117 in germinal cells of embryonic testis results in an increased apoptosis of germ cells and infertility in the following life periods [13].
Negative_regulation (loss) of CD117 in germ cells associated with reprotox - general 3 and apoptosis
5) Confidence 0.43 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 0.33 Pain Relevance 0
It can also act as a kit tyrosine kinase inhibitor, and, therefore, its expression has been analyzed in GIST and a broad variety of other malignancies [34].
Negative_regulation (inhibitor) of kit associated with gastrointestinal stromal tumor
6) Confidence 0.43 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 0.96 Pain Relevance 0
These observations suggest an inhibitory effect of c-kit and its ligand in breast cancer proliferation.
Negative_regulation (effect) of kit associated with breast cancer
7) Confidence 0.43 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 1.60 Pain Relevance 0.04
Inhibitors of c-kit
Negative_regulation (Inhibitors) of kit
8) Confidence 0.42 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 1.37 Pain Relevance 0.05
In vitro studies of small cell lung carcinoma cell lines showed a synergistic effect for c-kit and IGF-1R inhibitors in the induction of apoptosis [9,48].
Negative_regulation (inhibitors) of kit in lung associated with small cell lung carcinoma and apoptosis
9) Confidence 0.42 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1475889 Disease Relevance 1.56 Pain Relevance 0.03
Immunohistochemistry of the tumorectomy and autopsy specimens was positive for cytokeratins, neuron-specific enolase, synaptophysin, CD56, KIT and PDGFRA, and negative for chromogranin and thyroid transcriptional factor-1.
Negative_regulation (positive) of KIT in thyroid
10) Confidence 0.41 Published 2009 Journal Pathol. Int. Section Abstract Doc Link 19351368 Disease Relevance 0.61 Pain Relevance 0.08
Imatinib mesylate is a potent, selective inhibitor of PDGFR alpha (PDGFRa), PDGFR beta (PDGFRb), BCR-abl, KIT, ARG and c-FMS protein-tyrosine kinases [12,14].
Negative_regulation (inhibitor) of KIT associated with fibromyalgia
11) Confidence 0.41 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2892497 Disease Relevance 0.31 Pain Relevance 0
Imatinib mesylate (Gleevec®; Novartis Oncology) is an oral, small molecule tyrosine kinase inhibitor with good oral bioavailability.11 Imatinib exhibits potent inhibitory activity against KIT, platelet-derived growth factor receptor (PDGFR), ABL kinase and the chimeric BCR-ABL fusion oncoprotein of chronic myeloid leukemia.
Negative_regulation (inhibitor) of KIT in platelet associated with leukemia and bioavailability
12) Confidence 0.41 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 1.43 Pain Relevance 0.05
Preclinical data demonstrate that KIT kinase is inhibited in patients with imatinib-responsive GIST but reactivation of KIT and subsequent downstream phosphorylation occurs at the time of secondary resistance.
Negative_regulation (inhibited) of KIT associated with gastrointestinal stromal tumor
13) Confidence 0.41 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 1.05 Pain Relevance 0.08
A reduction in c-Kit staining was also noted in the study on diabetic patients undergoing gastric resection for cancer [20].
Negative_regulation (reduction) of c-Kit associated with cancer and diabetes mellitus
14) Confidence 0.39 Published 2008 Journal BMC Gastroenterol Section Body Doc Link PMC2442096 Disease Relevance 1.00 Pain Relevance 0.03
In addition, there may be pathways and strategies other than direct KIT inhibition, which are relevant to the biology of these tumors.
Negative_regulation (inhibition) of KIT associated with cancer
15) Confidence 0.36 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 1.05 Pain Relevance 0
Because of this, research efforts are focused on strategies which may be relevant in this disease other than direct KIT inhibition.
Negative_regulation (inhibition) of KIT associated with disease
16) Confidence 0.36 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 1.01 Pain Relevance 0
AMG-706 Finally, in a third abstract reported at the 2007 annual meeting of the American Society of Clinical Oncology, AMG-706, another multikinase inhibitor (VEGF/PDGF receptors, Kit and RET), was studied in a phase II trial of patients with advanced differentiated thyroid cancer or medullary thyroid cancer.
Negative_regulation (inhibitor) of Kit in thyroid associated with thyroid neoplasm
17) Confidence 0.32 Published 2010 Journal Journal of Thyroid Research Section Body Doc Link PMC2956973 Disease Relevance 1.16 Pain Relevance 0
The upregulation of these miRNAs was strongest associated with a dramatic loss of Kit transcript and its protein.
Negative_regulation (loss) of Kit
18) Confidence 0.32 Published 2007 Journal Mol Cancer Section Body Doc Link PMC2098778 Disease Relevance 0.57 Pain Relevance 0
Nearly all are immunohistologically positive to CD117 (KIT tyrosine kinase) as in our case, which differentiates it from true leiomyomas, neurofibroma, leiomyosarcoma and schwannoma [4].
Negative_regulation (positive) of CD117 associated with leiomyosarcoma, uterine fibroids, neurilemmoma and neurofibroma
19) Confidence 0.29 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC2219959 Disease Relevance 1.70 Pain Relevance 0.13
Hair depigmentation was also seen, a known marker of KIT inhibition (Moss et al 2003).
Negative_regulation (inhibition) of KIT in Hair
20) Confidence 0.26 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727778 Disease Relevance 1.20 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox